View in EDS

Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials.

Saved in:
Bibliographic Details
Title: Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials.
Authors: Harboe ZB; Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, Nordsjælland, Hillerød 3400, Denmark; Department of Bacteria, Parasites, and Fungi, Statens Serum Institute, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland. Electronic address: zitta.barrella.harboe@regionh.dk., Cordero E; Department of Medicine, School of Medicine, University of Seville, Seville, Spain; Clinical Unit of Infectious Diseases and Microbiology, Virgen del Rocío University Hospital, Seville, Spain; Institute of Biomedicine of Seville (IBiS), CIBER in Infectious Diseases, Seville, Spain; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland., Moran C; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland; Department of Infectious Diseases, Prince of Wales Hospital, Sydney, NSW, Australia., Kuijpers L; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland; Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands., Epaulard O; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland; Infectious Diseases, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique, CIC, 1406, Inserm-CHUGA-UGA, Grenoble, France., Vollaard A; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2025 Jul; Vol. 25 (7), pp. e378-e379. Date of Electronic Publication: 2025 May 09.
Publication Type: Letter
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40354795
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Harboe+ZB%22">Harboe ZB</searchLink>; Department of Pulmonary and Infectious Diseases, Copenhagen University Hospital, Nordsjælland, Hillerød 3400, Denmark; Department of Bacteria, Parasites, and Fungi, Statens Serum Institute, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland. Electronic address: zitta.barrella.harboe@regionh.dk.<br /><searchLink fieldCode="AU" term="%22Cordero+E%22">Cordero E</searchLink>; Department of Medicine, School of Medicine, University of Seville, Seville, Spain; Clinical Unit of Infectious Diseases and Microbiology, Virgen del Rocío University Hospital, Seville, Spain; Institute of Biomedicine of Seville (IBiS), CIBER in Infectious Diseases, Seville, Spain; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Moran+C%22">Moran C</searchLink>; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland; Department of Infectious Diseases, Prince of Wales Hospital, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Kuijpers+L%22">Kuijpers L</searchLink>; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland; Leiden University Center for Infectious Diseases (LU-CID), Leiden University Medical Center, Leiden, Netherlands.<br /><searchLink fieldCode="AU" term="%22Epaulard+O%22">Epaulard O</searchLink>; European Society of Microbiology and Infectious Diseases (ESCMID) Vaccine Study Group (EVASG), Basel, Switzerland; Infectious Diseases, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France; Groupe de Recherche en Infectiologie Clinique, CIC, 1406, Inserm-CHUGA-UGA, Grenoble, France.<br /><searchLink fieldCode="AU" term="%22Vollaard+A%22">Vollaard A</searchLink>; European Society of Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH), Basel, Switzerland; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101130150%22">The Lancet. Infectious diseases</searchLink> [Lancet Infect Dis] 2025 Jul; Vol. 25 (7), pp. e378-e379. <i>Date of Electronic Publication: </i>2025 May 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101130150 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4457 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214733099%22">14733099 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Infect Dis <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40354795
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1473-3099(25)00286-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e378
    Titles:
      – TitleFull: Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Harboe ZB
      – PersonEntity:
          Name:
            NameFull: Cordero E
      – PersonEntity:
          Name:
            NameFull: Moran C
      – PersonEntity:
          Name:
            NameFull: Kuijpers L
      – PersonEntity:
          Name:
            NameFull: Epaulard O
      – PersonEntity:
          Name:
            NameFull: Vollaard A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1474-4457
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The Lancet. Infectious diseases
              Type: main
ResultId 1